Actuate Therapeutics Receives U.S. Notice of Allowance for Patent Covering Elraglusib Oral Tablets
Globe Newswire•02/11/2026•08:00 ET
0
Key Highlights
- ➤USPTO issues Notice of Allowance for Actuate’s oral elraglusib tablet patent application
- ➤Phase 1/2 oral-tablet trial planned for Q1 2027 in advanced cancer patients
- ➤Daily oral dosing aims to provide sustained GSK-3β inhibition and plasma exposure
- ➤Elraglusib tablet could support monotherapy, combination, and maintenance treatment approaches
Expert Statements
Daniel Schmitt, President and Chief Executive Officer of Actuate Therapeutics
“The development of an optimized oral tablet dosage form marks an important advance in realizing elraglusib’s therapeutic potential”
Daniel Schmitt, President and Chief Executive Officer of Actuate Therapeutics
“Daily oral administration is expected to enable sustained plasma drug exposure and inhibition of GSK-3 in a tumor, potentially promoting sustained changes in immune cell dynamics that favor antitumor immune responses.”
Daniel Schmitt, President and Chief Executive Officer of Actuate Therapeutics
“This approach could also provide greater dosing flexibility and patient convenience and expand opportunities to investigate elraglusib as both a monotherapy and in combination with other cancer treatments.”
Andrew Mazar, Chief Operating Officer of Actuate Therapeutics
“The allowance of this patent application represents an important milestone in strengthening our intellectual property portfolio around oral formulations of elraglusib including protection for the oral tablet dosage form”
Andrew Mazar, Chief Operating Officer of Actuate Therapeutics
“With our imminent Phase 1/2 clinical trial, we anticipate being able to more fully explore the clinical potential of elraglusib in the next stage of development as we bring a new oral treatment option with a unique immunomodulatory mechanism of action to cancer patients in need.”
Oral tablet form expected to allow Company to optimize patient plasma exposure levels with convenient daily dosing of drug
Sustained plasma levels of elraglusib expected to have multiple effects on immune cell dynamics with potential to enhance anti-tumor immune response
Get started
Create a free account to read the full story.